Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
WALTHAM, Mass., Feb. 25, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences.
- Canaccord Genuity 11th Annual Musculoskeletal Conference – Orlando, FL (March 1, 2016)
Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Tuesday, March 1, 2016, at 3:00 pm EST. The conference immediately precedes the American Academy of Orthopedic Surgeons (AAOS) Annual Meeting and explores the current state of orthopedics, biologics, imaging, robotic surgery, tissue sculpting, and regenerative tissue companies.
- Cowen and Company 36th Annual Health Care Conference – Boston, MA (March 7-9, 2016)
Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Monday, March 7, 2016, at 4:00 pm EST.
The live webcasts may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcasts will be available on Histogenics’ website for approximately 45 days following the respective conferences.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
